Xoma Partners with Servier to Develop and Commercialise its Lead Anti-Inflammatory Drug
By Heather Cartwright
Pharma Deals Review: Vol 2011 Issue 1 (Table of Contents)
Published: 21 Jan-2011
DOI: 10.3833/pdr.v2011.i1.1422 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
US-based Xoma has signed a regional licensing deal with the French pharmaceutical company Les Laboratoires Servier to develop and commercialise its leading anti-inflammatory drug candidate, XOMA 052, in multiple indications...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS